European Lung Cancer Congress | Conference

Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC

March 31st 2023

Taletrectinib continued to demonstrate meaningful efficacy in the form of a durable objective response rate and a high intracranial ORR with acceptable tolerability in both TKI-naïve and crizotinib-pretreated patients with ROS1-positive non–small cell lung cancer.

Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC

March 30th 2023

The addition of cemiplimab to platinum-doublet chemotherapy continued to provide a clinically meaningful and statistically significant improvement in clinical benefit over chemotherapy alone in patients with advanced non–small cell lung cancer, irrespective of histology or PD-L1 expression level.

Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC

March 30th 2023

Neoadjuvant nivolumab plus chemotherapy produced a long-term event-free survival benefit vs chemotherapy alone in patients with resectable non–small cell lung cancer, independent of whether patients underwent minimally invasive surgery or thoracotomy or complete or partial resection of the lung.

Amivantamab Provides Long-term Clinical Benefit in Post-Platinum EGFR Exon 20 Insertion+ NSCLC

March 30th 2023

Amivantamab continued to be tolerable and efficacious in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease progressed on platinum-based chemotherapy.

Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC

March 29th 2023

Up-front treatment with osimertinib reduced the risk of brain progression-free survival but provided a comparable overall survival benefit compared with sequential treatment with gefitinib followed by osimertinib in patients with advanced non–small cell lung cancer harboring EGFR mutations.

Dr. Ramalingam on Treatment After Osimertinib in EGFR-Mutant NSCLC

March 27th 2021

Suresh S. Ramalingam, MD, FASCO, deputy director, director, Lung Cancer Program, Winship Cancer Institute of Emory University, professor, assistant dean, Roberto C. Goizueta Distinguished Chair for Cancer Research, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses treatment after osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).

Durvalumab Use Differs in Real-World, PACIFIC Stage III NSCLC Populations

March 27th 2021

More patients with stage III non–small cell lung cancer received sequential chemoradiation and delayed the time to durvalumab treatment in a real-world setting compared with those enrolled on the phase 3 PACIFIC trial.

Dr. Subramanian on Real-World Data With EGFR TKIs in Advanced NSCLC

March 27th 2021

Janakiraman Subramanian, MD, discusses the use of EGFR TKIs in the treatment of patients with non–small cell lung cancer.

Frontline Osimertinib Showcases Real-World Safety, Efficacy in EGFR+ Advanced NSCLC

March 27th 2021

Osimertinib (Tagrisso) showcased encouraging efficacy and acceptable safety in patients with EGFR-positive, advanced non–small cell lung cancer. according to real-world findings from an observational, multicenter study.

Dr. Robinson on the Updated Results of the KEYNOTE-407 Trial in Squamous NSCLC

March 26th 2021

Andrew G. Robinson, MD, MSc, FRCPC, discusses the updated results of the phase 3 KEYNOTE-407 trial in squamous non–small cell lung cancer.

Dr. Bazhenova on a Correlative Analysis of the KRYSTAL-1 Trial in Advanced NSCLC

March 26th 2021

Lyudmila A. Bazhenova, MD, discusses the results of a preliminary exploratory correlative analysis of the phase 1/2 KRYSTAL-1 trial in advanced non–small cell lung cancer.

Chemotherapy Plus Immunotherapy Shows No Benefit Following Osimertinib in EGFR+ NSCLC

March 26th 2021

Treatment with chemotherapy plus immunotherapy did not demonstrate significant clinical benefit over chemotherapy alone in patients with EGFR-mutated non–small cell lung cancer after progression on osimertinib.

Prior Immunotherapy or Osimertinib Negatively Impacts Outcomes With Subsequent Atezolizumab in NSCLC

March 26th 2021

Previous exposure to immune checkpoint inhibitors or osimertinib has been linked with poor outcomes in patients with non–small cell lung cancer who were receiving a subsequent atezolizumab-containing regimen.

AMG 757 Shows Early Efficacy, Safety in Small Cell Lung Cancer

March 26th 2021

The half-life extended, DLL3-targeting bispecific T-cell engager AMG 757 demonstrated early signals of efficacy and a favorable safety profile in patients with small cell lung cancer.

Adagrasib Demonstrates Favorable Efficacy, Pharmacokinetic Profile in Advanced KRAS G12C+ NSCLC

March 25th 2021

Adagrasib yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C–mutant advanced non–small cell lung cancer.

Dr. Garassino on the Rationale for the PACIFIC-6 Trial in NSCLC

March 25th 2021

Marina Chiara Garassino, MD, discusses the rationale for the phase 2 PACIFIC-6 trial in non–small cell lung cancer.

Camrelizumab Plus Chemo Prolongs PFS in Advanced Squamous NSCLC

March 25th 2021

First-line treatment with camrelizumab, an investigational PD-1 inhibitor, plus chemotherapy induced robust and durable clinical responses in patients with advanced squamous non–small cell lung cancer.

FASN Inhibitor AZ12756122 Reduces Resistance Properties in EGFR TKI–Resistant, EGFR-Mutant NSCLC Models

March 25th 2021

The fatty acid synthase inhibition caused by AZ12756122 could represent a promising therapeutic alternative to overcome resistance to EGFR TKIs because of the synergistic interaction that it has with osimertinib and its ability to reduce cancer stem cell properties in EGFR-mutant non–small cell lung cancer cell models.

Nivolumab/Ipilimumab Plus Short-Course Chemo Improves OS Regardless of TMB Status in Advanced NSCLC

March 25th 2021

The frontline combination of nivolumab and ipilimumab plus 2 cycles of chemotherapy demonstrated an improvement in overall survival vs chemotherapy alone in patients with advanced non–small cell lung cancer regardless of tumor mutational burden status in the tissue or blood.

Atezolizumab Regimen Improves OS After TKI Failure in EGFR+ NSCLC

April 14th 2019

Atezolizumab plus bevacizumab, carboplatin, and paclitaxel has emerged as a potential new standard of care for patients with EGFR-positive metastatic nonsquamous non–small cell lung cancer who have failed prior TKIs.